Cladribine and bendamustine exhibit inhibitory activity in dexamethasone-sensitive and -resistant multiple myeloma cells

American Journal of Translational Research

Volumn 5, Issue 1, 2013, Pages 36-46

  Cai, Bo ^a,b   Wang, Shuiliang ^b   Huang, Jingcao ^b,d   Lee, Choon Kee ^c,e   Gao, Chunji ^a   Liu, Bolin ^b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b Department of Pathology ^*  (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^e Montrose Memorial Hospital   (United States)

Author keywords

Apoptosis; Bendamustine; Cladribine; Dexamethasone resistance; DNA damage response; Multiple myeloma

Indexed keywords

BENDAMUSTINE; C 4438; CASPASE 3; CASPASE 8; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CLADRIBINE; DEXAMETHASONE; HISTONE H2A; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DNA DAMAGE; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MULTIPLE MYELOMA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; S PHASE CELL CYCLE CHECKPOINT; WESTERN BLOTTING;

EID: 84872792551     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Jemal A, Siegel R, Xu J and Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Liliemark J. The clinical pharmacokinetics of cladribine. Clin Pharmacokinet 1997; 32: 120-131.
3. Seto S, Carrera CJ, Kubota M, Wasson DB and Carson DA. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest 1985; 75: 377-383.
4. Hjertner O, Borset M and Waage A. Comparison of the effects of 2-chlorodeoxyadenosine and melphalan myeloma cell lines. Leuk Res 1996; 20: 155-160.
5. Goodman GR, Burian C, Koziol JA and Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 2003; 21: 891-896.
6. Karlsson KA, Stromberg M, Jonsson V, Mulligan SP, Liliemark J and Juliusson G. Cladribine (CdA) gives longer response duration than fudarabine (F) and high-dose intermittent chlorambucil (Chl) as frst-line treatment of symptomatic chronic lymphocytic leukemia (CLL). First results from the international randomized phase III trial. Blood 2007; 110: 194a-194a.
7. Robak T, Jamroziak K, Gora-Tybor J, Stella-Holowiecka B, Konopka L, Ceglarek B, Warzocha K, Seferynska I, Piszcz J, Calbecka M, Kostyra A, Dwilewicz-Trojaczek J, Dmoszynska A, Zawilska K, Hellmann A, Zdunczyk A, Potoczek S, Piotrowska M, Lewandowski K and Blonski JZ. Comparison of cladribine plus cyclophosphamide with fudarabine plus cyclophosphamide as frst-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). J Clin Oncol 2010; 28: 1863-1869.
8. Robak T, Blonski JZ, Wawrzyniak E, Gora-Tybor J, Palacz A, Dmoszynska A, Konopka L, Warzocha K and Jamroziak K. Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion: report from the Polish Adult Leukemia Group. Cancer 2009; 115: 94100.
9. Bertazzoni P, Rabascio C, Gigli F, Calabrese L, Radice D, Calleri A, Gregato G, Negri M, Liptrott SJ, Bassi S, Nassi L, Sammassimo S, Laszlo D, Preda L, Pruneri G, Orlando L and Martinelli G. Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients. Leuk Lymphoma 2010; 51: 1485-1493.
10. Sigal DS, Miller HJ, Schram ED and Saven A. Beyond hairy cell: the activity of cladribine in other hematologic malignancies. Blood 2010; 116: 2884-2896.
11. Holowiecki J, Grosicki S, Giebel S, Robak T, Kyrcz-Krzemien S, Kuliczkowski K, Skotnicki AB, Hellmann A, Sulek K, Dmoszynska A, Kloczko J, Jedrzejczak WW, Zdziarska B, Warzocha K, Zawilska K, Komarnicki M, Kielbinski M, Piatkowska-Jakubas B, Wierzbowska A, Wach M and Haus O. Cladribine, But Not Fludarabine, Added to Daunorubicin and Cytarabine During Induction Prolongs Survival of Patients With Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Study. J Clin Oncol 2012; 30: 2441-2448.
12. Dimopoulos MA, Kantarjian HM, Estey EH and Alexanian R. 2-Chlorodeoxyadenosine in the treatment of multiple myeloma. Blood 1992; 80: 1626.
13. Niesvizky R, Siegel D and Michaeli J. 2-Chlorodeoxyadenosine for multiple myeloma. Blood 1993; 81: 868-869.
14. Guchelaar HJ, Richel DJ and Schaafsma MR. Clinical and toxicological aspects of the antineoplastic drug cladribine: a review. Ann Hematol 1994; 69: 223-230.
15. Nagourney RA, Evans SS, Messenger JC, Su YZ and Weisenthal LM. 2 chlorodeoxyadenosine activity and cross resistance patterns in primary cultures of human hematologic neoplasms. Br J Cancer 1993; 67: 10-14.
16. Bagley RG, Roth S, Kurtzberg LS, Rouleau C, Yao M, Crawford J, Krumbholz R, Lovett D, Schmid S and Teicher BA. Bone marrow CFUGM and human tumor xenograft efficacy of three antitumor nucleoside analogs. Int J Oncol 2009; 34: 1329-1340.
17. Ma J, Wang S, Zhao M, Deng XS, Lee CK, Yu XD and Liu B. Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma. BMC Cancer 2011; 11: 255.
18. Leoni LM, Bailey B, Reifert J, Bendall HH, Zeller RW, Corbeil J, Elliott G and Niemeyer CC. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008; 14: 309-317.
19. Kalaycio M. Bendamustine: a new look at an old drug. Cancer 2009; 115: 473-479.
20. Chow KU, Boehrer S, Geduldig K, Krapohl A, Hoelzer D, Mitrou PS and Weidmann E. In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine. Haematologica 2001; 86: 485-493.
21. Kanekal S, Crain B, Elliott G and Multani PS. SDX-105 (Treanda (TM)) enhances the tumor growth inhibitory effect of rituximab in Daudi lymphoma xenografts. Blood 2004; 104: 229b-229b.
22. Damaj G, Malard F, Hulin C, Caillot D, Garidi R, Royer B, Marit G, Stoppa AM, Banos A, Morineau N, Moreau P, Fitoussi O and Tiab M. Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program. Leuk Lymphoma 2012; 53: 632-634.
23. Ramasamy K, Hazel B, Mahmood S, Corderoy S and Schey S. Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease. Br J Haematol 2011; 155: 632-634.
24. Lentzsch S, O'Sullivan A, Kennedy RC, Abbas M, Dai L, Pregja SL, Burt S, Boyiadzis M, Roodman GD, Mapara MY, Agha M, Waas J, Shuai Y, Normolle D and Zonder JA. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood 2012; 119: 4608-4613.
25. Greenstein S, Krett NL, Kurosawa Y, Ma C, Chauhan D, Hideshima T, Anderson KC and Rosen ST. Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells. Exp Hematol 2003; 31: 271-282.
26. Lee CK, Wang S, Huang X, Ryder J and Liu B. HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells. Cancer Lett 2010; 296: 233-240.
27. Korycka A, Lech-Maranda E and Robak T. Novel purine nucleoside analogues for hematological malignancies. Recent Pat Anticancer Drug Discov 2008; 3: 123-136.
28. Robak T, Korycka A, Kasznicki M, WrzesienKus A and Smolewski P. Purine nucleoside an-alogues for the treatment of hematological malignancies: pharmacology and clinical applications. Curr Cancer Drug Targets 2005; 5: 421-444.
29. Chang JE and Kahl BS. Bendamustine for treatment of chronic lymphocytic leukemia. Expert Opinion on Pharmacotherapy 2012; 13: 1495-1505.
30. Rasschaert M, Schrijvers D, Van den Brande J, Dyck J, Bosmans J, Merkle K and Vermorken JB. A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors. Anti-Cancer Drugs 2007; 18: 587-595.
31. Chauhan D, Pandey P, Ogata A, Teoh G, Treon S, Urashima M, Kharbanda S and Anderson KC. Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism. Oncogene 1997; 15: 837-843.
32. Hideshima T, Nakamura N, Chauhan D and Anderson KC. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 2001; 20: 5991-6000.
33. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS and Jove R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10: 105-115.
34. Frankfurt O and Rosen ST. Mechanisms of glucocorticoid-induced apoptosis in hematologic malignancies: updates. Curr Opin Oncol 2004; 16: 553-563.
35. Monaghan KA, Khong T, Burns CJ and Spencer A. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells. Leukemia 2011; 25: 1891-1899.
36. Mahindra A, Cirstea D and Raje N. Novel therapeutic targets for multiple myeloma. Future Oncol 2010; 6: 407-418.
37. Younes H, Leleu X, Hatjiharissi E, Moreau AS, Hideshima T, Richardson P, Anderson KC and Ghobrial IM. Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma. Clin Cancer Res 2007; 13: 3771-3775.